Senju Pharmaceutical has filed a patent for medicaments that treat or prevent diseases associated with abnormal extracellular matrix (ECM) in the corneal endothelium. The medicaments contain a TGF-beta signal inhibiting agent, with a specific example being 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide. The diseases include Fuchs’ endothelial corneal dystrophy and its associated symptoms such as blurred vision, eye pain, and corneal opacity. GlobalData’s report on Senju Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Senju Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Senju Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Senju Pharmaceutical's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Medicament for treating or preventing corneal endothelium abnormality

Source: United States Patent and Trademark Office (USPTO). Credit: Senju Pharmaceutical Co Ltd

A recently filed patent (Publication Number: US20230310402A1) describes a medicament for treating or preventing diseases, disorders, or conditions associated with extracellular matrix (ECM) abnormality in the corneal endothelium. The medicament contains an effective amount of a TGF-beta signal inhibiting agent.

One specific disorder that the medicament targets is Fuchs' endothelial corneal dystrophy. This disorder is characterized by various symptoms such as photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, and corneal opacity.

The TGF-beta signal inhibiting agent in the medicament can include various compounds such as 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide, BMP-7, anti-TGF-beta antibody, anti-TGF-beta receptor antibody, siRNA of TGF-beta, siRNA of a TGF-beta receptor, shRNA of TGF-beta, shRNA of a TGF-beta receptor, an aptamer of TGF-beta, an aptamer of a TGF-beta receptor, an antisense oligonucleotide of TGF-beta, 6,7-dimethoxy-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridine-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinolone, 3-(6-methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide, 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, 6-(4-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine, 2-(5-chloro-2-fluorophenyl)-4-[(4-pyridinyl)amino]pteridine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-quinoline, pharmaceutically acceptable salts or solvates thereof, or solvates of the pharmaceutically acceptable salts. Alternatively, the TGF-beta signal inhibiting agent can specifically be 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide or a pharmaceutically acceptable salt thereof.

The medicament can be used for treating or preventing diseases, disorders, or conditions associated with ECM abnormality in the corneal endothelium of primates, including humans. It can be administered as eye-drops and may also contain additional medicinal components.

In summary, the patent describes a medicament for treating or preventing diseases, disorders, or conditions associated with ECM abnormality in the corneal endothelium. It contains a TGF-beta signal inhibiting agent, with a specific focus on Fuchs' endothelial corneal dystrophy. The medicament can be administered as eye-drops and may include additional medicinal components.

To know more about GlobalData’s detailed insights on Senju Pharmaceutical, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies